摘要目的 测定8例造血干细胞移植术后人巨细胞病毒(HCMV)临床分离株对更昔洛韦(GCV)的敏感性,监测该类患者对更昔洛韦的耐药状况.方法 收集8例造血干细胞移植术后发生HCMV感染而接受GCV治疗的患者血液或尿液标本,采用HELF细胞培养法分离并鉴定HCMV临床株,50％终点法测定各临床毒株的感染性滴度TCID50,并用MTT法测定各毒株对更昔洛韦的敏感性.结果 8株HCMV病毒液的TCID50分别为:10-4.12/0.1～10-4 62/0.1 ml;8株临床HCMV分离株对更昔洛韦的半数病毒抑制浓度IC50分别为0.482 ～1.519 mg/L.结论 该实验HCMV临床分离株对更昔洛韦敏感性均较高,未发现临床耐药株.

abstractsObjective To investigate the susceptibilities of HCMV clinical strains isolated to ganciclovir from the patients after hematopoietic stem cell transplantation.Methods Eight HCMV clinical isolates were isolated from the blood or the urine of hematopoietic stem cell transplantation recipients who had been treated with GCV.Tissue cell infection median dose(TCID50) were calculated by Reed-Muench method.Drug susceptibility was determined by MTT assay.Results TCID50 values of eight HCMV clinical strains were 10-4.12/0.1ml,10-4.29/0.1ml,10-4.3/0.1ml,10-4.4/0.1ml 10-4.42/0.1ml,10-4.5/0.1ml,10-4.52/0.1ml and 10-4.62/0.1ml respectively.50％ inhibitory concentration(IC50) to GCV of eight HCMV clinical strains were 0.638,1.438,0.965,0.698,0.482,1.167,1.519,1.511 mg/L respectively.Conclusion Our results suggest that resistant HCMV strains are not prevalent in Guangzhou.Continuous monitoring of HCMV is needed to understand the antiviral resistance status of the virus in patients after hematopoietic stem cell transplantation and guide its clinical management.